Less Ads, More Data, More Tools Register for FREE

Pin to quick picksConcurrent Technologies Regulatory News (CNC)

Share Price Information for Concurrent Technologies (CNC)

Share Price is delayed by 15 minutes
Get Live Data
250.00    0.00 (0.00%)
Bid:
245.00
Ask:
255.00
Spread: 10.00 (4.082%)
Market Cap: £227.11m
CNC Live PriceLast checked at - London Stock Exchange

Intraday Concurrent Technologies Share Chart

Supply Agreement

13 Jul 2022 07:00

RNS Number : 2508S
Concurrent Technologies PLC
13 July 2022
 

 

This announcement contains inside information

 

13 July 2022

Concurrent Technologies Plc

("Concurrent Technologies" or the 'Company')

Supply Agreement with Global Medical Technology Company

 

Concurrent Technologies, a world leading specialist in the design and manufacture of high-end embedded computer boards for critical applications, has entered into a supply agreement with a Fortune 500 global medical technology company, and has received an initial USD$2.2 million order for first year product shipments. Initial shipments have already commenced for qualification purposes with volume shipments scheduled to start at the end of 2022. The customer is then expected to place similar size orders on an annual basis for several years to come.

The customer's needs were multi-faceted and challenging. Concurrent Technologies developed a product that maintained backwards compatibility with the external interfaces of the prior product; demonstrated the ability to manage and overcome issues that would prevent multi-year production without changes; and met all the customer's quality and supply chain requirements. Concurrent Technologies also ported the customer's application software to work seamlessly on the new hardware, accelerating the introduction of the customer's next generation machine.

Dr. Miles Adcock, CEO of Concurrent Technologies, commented: "We pride ourselves on delivering extremely reliable products to a very high-quality standard which suits customers from many vertical market segments including medical. The required product was developed at pace in line with the expectation we have set for increasing the cadence of new product introductions. With the customer intending to place similar size orders on an annual basis for several years to come, this is expected to provide a steady revenue stream that is wholly accretive to our current business."

 

Enquiries:

Concurrent Technologies Plc

Miles Adcock, CEO +44 (0)1206 752626

 

SEC Newgate (Financial PR)

Bob Huxford +44 (0)20 3757 6880

Isabelle Smurfit +44 (0)20 3757 6880

Group email concurrent@secnewgate.co.uk

 

Cenkos Securities Plc (NOMAD)

Neil McDonald +44 (0)131 220 9771

Peter Lynch +44 (0)131 220 9772

 

About Concurrent Technologies Plc

Concurrent Technologies Plc develops and manufactures high-end embedded computer products for use in a wide range of high-performance, long-life cycle applications within the telecommunications, defence, security, telemetry, scientific and aerospace markets, including applications within extremely harsh environments. The processor products feature Intel® processors, including the latest 9th generation embedded Intel® Core™ processors, Intel® Xeon® and Intel® Atom™ processors. The products are designed to be compliant with industry specifications and support many of today's leading embedded Operating Systems. The products are sold world-wide.

For more information on Concurrent Technologies Plc and its products please visit www.gocct.com.

All trademarks, registered trademarks and trade names used in this announcement are the property of their respective owners.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
AGRSFSEEEEESEDW
Date   Source Headline
14th May 20267:00 amRNSPosting of Annual Report and Notice of AGM
13th Apr 20267:01 amRNSBoard change
13th Apr 20267:00 amRNSFinal results for the year ended 31 December 2025
31st Mar 20265:24 pmRNSBlock Admission Application
30th Mar 20267:00 amRNSNotice of Results and Investor Presentation
10th Mar 20267:00 amRNSLaunch of Next-Generation Computing Products
25th Feb 20267:00 amRNSHolding(s) in Company
16th Feb 20267:00 amRNSAppointment of Nominated Adviser and Broker
27th Jan 20267:00 amRNSNew Managing Director of Products Appointed
26th Jan 20267:00 amRNSNew Product Announcement
20th Jan 20267:00 amRNSTrading Update
23rd Dec 20257:00 amRNSUpdate on Expanded HQ and Manufacturing Facility
23rd Dec 20257:00 amRNSUpdate on Expanded HQ and Manufacturing Facility
12th Dec 20254:43 pmRNSExercise of Options and TVR
9th Dec 202512:46 pmRNSExercise of Options, Director Dealing and TVR
5th Dec 202512:15 pmRNSExercise of Share Options and Total Voting Rights
27th Nov 20254:46 pmRNSExercise of Options, Director Dealing and TVR
1st Oct 20257:00 amRNSIssue of Share Options and PDMR Dealing
19th Sep 20255:36 pmRNSDirector Share Dealing
19th Sep 20257:00 amRNS$5.25m US Defence Contract Secured
8th Sep 20257:00 amRNSInterim Results
4th Sep 20257:00 amRNSRecord UK defence contract secured for £4m
20th Aug 20257:00 amRNSNew Product Launch
13th Aug 20254:20 pmRNSInvestor Meet Company Presentation Update
12th Aug 20257:00 amRNSLaunch of Compact Computer System
29th Jul 20257:00 amRNSNotice of Results and Investor Presentation
16th Jul 20255:25 pmRNSHolding(s) in Company
15th Jul 20257:00 amRNSH1 FY25 Trading Update
8th Jul 20252:13 pmRNSExercise of Options, New Ordinary Shares and TVR
1st Jul 20255:51 pmRNSHolding(s) in Company
25th Jun 20257:00 amRNSHolding(s) in Company
18th Jun 20252:19 pmRNSExercise of Options, New Ordinary Shares and TVR
13th Jun 20257:00 amRNSResults of Annual General Meeting
23rd May 20251:07 pmRNSExercise of Options, New Ordinary Shares and TVR
16th May 202510:53 amRNSPosting of Annual Report and Notice of AGM
15th May 20251:28 pmRNSHolding(s) in Company
8th May 20257:00 amRNSExercise of Options, New Ordinary Shares and TVR
28th Apr 20257:00 amRNSExercise of Options
24th Apr 20251:25 pmRNSExercise of Options, Director Dealing and TVR
23rd Apr 20254:01 pmRNSHolding(s) in Company
14th Apr 20257:00 amRNSFinal Results for the year ended 31 December 2024
7th Apr 20257:00 amRNSNotice of Results and Investor Presentation
31st Mar 20257:00 amRNSLease agreed for new HQ & manufacturing facility
17th Mar 202510:46 amRNSHolding(s) in Company
3rd Mar 20257:00 amRNSNew Product Announcement
28th Feb 20257:00 amRNSDirector Share Dealing
13th Feb 20257:00 amRNSCommencement of Trading on OTCQX in the U.S.
27th Jan 20257:00 amRNSMajor VME Product Order from Long-Term Customer
17th Jan 20259:22 amRNSHolding(s) in Company
16th Jan 20257:00 amRNSTrading Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.